Evidence map›Paper›PMID 39324706›Full record

ArticleCancer research communications2024

ATF6 Promotes Colorectal Cancer Growth and Stemness by Regulating the Wnt Pathway.

Jeffrey J Rodvold, Matthew Grimmer, Karen Ruiz, Scot A Marsters, Ioanna Oikonomidi, Eileen Tan-Aristy, Victoria C Pham, Tamal Sarkar, Jonathan M Harnoss, Whitney Shatz-Binder and 7 more

Abstract read
In one paragraph

Article in Cancer research communications, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Jeffrey J RodvoldDepartment of Research Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-4873-210X
Matthew GrimmerDepartment of Computational Science, Genentech, Inc., South San Francisco, California.ORCID 0000-0001-5184-9168
Karen RuizDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-8083-7630
Scot A MarstersDepartment of Research Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-8517-0994
Ioanna OikonomidiDepartment of Research Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0003-1657-962X
Eileen Tan-AristyDepartment of Research Oncology, Genentech, Inc., South San Francisco, California.ORCID 0009-0006-1617-6694
Victoria C PhamDepartment of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., South San Francisco, California.ORCID 0009-0009-9281-8806
Tamal SarkarDepartment of General, Visceral, Thoracic, and Transplantation Surgery, University Hospital Giessen, Giessen, Germany.ORCID 0009-0003-7053-530X
Jonathan M HarnossDepartment of General, Visceral, Thoracic, and Transplantation Surgery, University Hospital Giessen, Giessen, Germany.ORCID 0000-0002-4272-5769
Whitney Shatz-BinderDepartment of Pharmaceutical Development, Genentech, Inc., South San Francisco, California.ORCID 0000-0003-2996-501X
Zora D ModrusanDepartment of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., South San Francisco, California.ORCID 0009-0003-5647-5195
Thomas D WuDepartment of Computational Science, Genentech, Inc., South San Francisco, California.ORCID 0000-0003-4505-4531
Jennie R LillDepartment of Microchemistry, Proteomics, and Lipidomics, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-7142-253X
Elisia VillemureDepartment of Discovery Chemistry, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-0902-5189
Joachim RudolphDepartment of Discovery Chemistry, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-0806-6106
Felipe de Sousa E MeloDepartment of Discovery Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-9558-3098
Avi AshkenaziDepartment of Research Oncology, Genentech, Inc., South San Francisco, California.ORCID 0000-0002-6890-4589

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

significanceATF6 intervention reduces colorectal cancer cell and organoid viability by interrupting dysregulated Wnt signaling, identifying a novel facilitator and potential therapeutic target in colorectal cancer.

Indexed as

Activating Transcription Factor 6Colorectal NeoplasmsNeoplastic Stem CellsWnt Signaling PathwayAnimalsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansMiceActivating Transcription Factor 6ATF6 protein, human

Identifiers

PMID39324706
PMCPMC11492184

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.